Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: a cohort study from OpenSAFELY
COVID-19 Vaccines
SARS-CoV-2
EHR data
Vaccination
R
COVID-19
3. Good health
Chickenpox Vaccine
Cohort Studies
03 medical and health sciences
0302 clinical medicine
England
Medicine
Humans
England/epidemiology
COVID-19/epidemiology
Vaccine breakthrough
Research Article
Retrospective Studies
DOI:
10.1186/s12916-022-02422-0
Publication Date:
2022-07-05T18:08:38Z
AUTHORS (42)
ABSTRACT
Abstract Background While the vaccines against COVID-19 are highly effective, vaccine breakthrough is possible despite being fully vaccinated. With SARS-CoV-2 variants still circulating, describing characteristics of individuals who have experienced breakthroughs could be hugely important in helping to determine may at greatest risk. Methods approval NHS England, we conducted a retrospective cohort study using routine clinical data from OpenSAFELY-TPP database vaccinated individuals, linked secondary care and death registry described those experiencing breakthroughs. Results As 1st November 2021, total 15,501,550 were identified as COVID-19, with median follow-up time 149 days (IQR: 107–179). From within this population, 579,780 (<4%) reported positive test. For every 1000 years patient time, corresponding incidence rate (IR) was 98.06 (95% CI 97.93–98.19). There 28,580 COVID-19-related hospital admissions, 1980 critical admissions 6435 deaths; IRs 4.77 4.74–4.80), 0.33 0.32–0.34) 1.07 1.06–1.09), respectively. The highest rates seen homes patients chronic kidney disease, dialysis, transplant, haematological malignancy or immunocompromised. Conclusions majority cases England mild, some differences been several groups. it note that these findings simply descriptive cannot used answer why certain groups higher than others, emergence Omicron variant coupled number tests occurring concerning numbers (and boosted) increases lengthens, so too will cases. Additional analyses, assess waning between different variants, aimed identifying risk, needed.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (19)
CITATIONS (21)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....